UA129400C2 - Застосування церебролізину для зменшення смертності в пацієнтів з cadasil - Google Patents

Застосування церебролізину для зменшення смертності в пацієнтів з cadasil Download PDF

Info

Publication number
UA129400C2
UA129400C2 UAA202001881A UAA202001881A UA129400C2 UA 129400 C2 UA129400 C2 UA 129400C2 UA A202001881 A UAA202001881 A UA A202001881A UA A202001881 A UAA202001881 A UA A202001881A UA 129400 C2 UA129400 C2 UA 129400C2
Authority
UA
Ukraine
Prior art keywords
cerebrolysin
use according
treated
patient
patients
Prior art date
Application number
UAA202001881A
Other languages
English (en)
Ukrainian (uk)
Inventor
Штефан Вінтер
Штефан ВИНТЕР
Герберт Мьослер
Original Assignee
Евер Нейро Фарма Гмбх
Эвер Нейро Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Евер Нейро Фарма Гмбх, Эвер Нейро Фарма Гмбх filed Critical Евер Нейро Фарма Гмбх
Publication of UA129400C2 publication Critical patent/UA129400C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
UAA202001881A 2017-08-28 2018-08-28 Застосування церебролізину для зменшення смертності в пацієнтів з cadasil UA129400C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (1)

Publication Number Publication Date
UA129400C2 true UA129400C2 (uk) 2025-04-16

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202001881A UA129400C2 (uk) 2017-08-28 2018-08-28 Застосування церебролізину для зменшення смертності в пацієнтів з cadasil

Country Status (15)

Country Link
US (1) US12589118B2 (enExample)
EP (2) EP3449931B1 (enExample)
JP (1) JP7281450B2 (enExample)
KR (1) KR102676274B1 (enExample)
CN (1) CN111050780B (enExample)
AU (1) AU2018326339A1 (enExample)
CA (1) CA3073991A1 (enExample)
EA (1) EA202090108A1 (enExample)
ES (2) ES2767070T3 (enExample)
HR (1) HRP20200031T1 (enExample)
MX (1) MX2020002267A (enExample)
PH (1) PH12020500376A1 (enExample)
PL (2) PL3449931T3 (enExample)
UA (1) UA129400C2 (enExample)
WO (1) WO2019042983A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198037A1 (en) * 2019-03-25 2020-10-01 The University Of Vermont Methods to promote cerebral blood flow in the brain
EP4114843B1 (en) 2020-07-13 2023-08-16 EVER Neuro Pharma GmbH Method for producing a mammalian brain protein hydrolysate
KR20240159455A (ko) * 2021-06-02 2024-11-05 리제너론 파마슈티칼스 인코포레이티드 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE154608T1 (de) 1990-04-12 1997-07-15 Ebewe Arzneimittel Verwendung einer mischung von peptiden and aminosäuren für die prophylaxis oder behandlung von dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
CA2734646C (en) 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates

Also Published As

Publication number Publication date
WO2019042983A1 (en) 2019-03-07
JP2020531568A (ja) 2020-11-05
US20200376040A1 (en) 2020-12-03
PH12020500376A1 (en) 2020-12-07
ES2901508T3 (es) 2022-03-22
CA3073991A1 (en) 2019-03-07
AU2018326339A1 (en) 2020-03-05
EP3449931A1 (en) 2019-03-06
EP3675879A1 (en) 2020-07-08
CN111050780A (zh) 2020-04-21
CN111050780B (zh) 2023-11-03
JP7281450B2 (ja) 2023-05-25
PL3449931T3 (pl) 2020-06-01
KR102676274B1 (ko) 2024-06-18
MX2020002267A (es) 2020-10-22
EP3675879B1 (en) 2021-09-15
EA202090108A1 (ru) 2020-03-31
ES2767070T3 (es) 2020-06-16
HRP20200031T1 (hr) 2020-03-20
KR20200045503A (ko) 2020-05-04
PL3675879T3 (pl) 2022-02-14
US12589118B2 (en) 2026-03-31
EP3449931B1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
JP7379615B2 (ja) 補体活性のモジュレーター
Prokop et al. Microglia actions in Alzheimer’s disease
JP2000507828A (ja) アルツハイマー病の診断および治療法
JP2021505565A (ja) 補体活性のモジュレータ
JP7301741B2 (ja) 補体活性のモジュレータ
Gulati et al. A Novel Neuroregenerative Approach Using ET B Receptor Agonist, IRL-1620, to Treat CNS Disorders.
US12589118B2 (en) Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Tan et al. Vagus nerve stimulation (VNS) inhibits cardiac mast cells activation and improves myocardial atrophy after ischemic stroke
Dhapola et al. Exploring retinal neurodegeneration in Alzheimer’s disease: a molecular and cellular perspective
AU2011314074B2 (en) ND2 peptides and methods of treating neurological disease
Kozin et al. Enalaprilat inhibits zinc-dependent oligomerization of metal-binding domain of amyloid-beta isoforms and protects human neuroblastoma cells from toxic action of these isoforms
Wang et al. Age-and sex-specific regulation of serine racemase in the retina of an Alzheimer's disease mouse
JP7419229B2 (ja) 方法
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
EA040978B1 (ru) Применение церебролизина
AU2019334965A1 (en) Methods and compositions for inducing neural plasticity
HRP20220370A1 (hr) Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata
Jiang The effect of remote ischemic preconditioning on astrocyte phenotypes and responses
EP2746402A1 (en) Method of prognosis of Alzheimers disease and substrates for use therein
Lina Palaiodimou et al. FABRY DISEASE: CLINICAL CHARACTERISTICS, DIAGNOSIS AND MANAGEMENT
Zheng et al. The novel PSD-95 inhibitor BXOS110 provides neuroprotection in acute ischemic stroke
飯島圭哉 Transplanted microvascular endothelial cells promote oligodendrocyte precursor cell survival in ischemic demyelinating lesions.
Banfi et al. A CASE OF CHRONIC IMMUNE SENSORY POLIRADICU-LOPATHY (CISP) RESPONSIVE TO IMMUNE MODULATING TREATMENT
Oyesola et al. SLEEP DEPRIVATION AND COFFEE CONSUMPTION INDUCED CHANGES IN BMI, BLOOD PRESSURE AND BLOOD GLUCOSE IN MALE WISTAR ALBINO RATS